mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well-tolerated and efficacious in rodent models
Neha Agrawal, Louis S. Ates, Stefan A. Schille, Anuhar Chaturvedi, Janina Vogt, Nataša Vukovic, Charles L. Dulberger, Annette B. Vogel, Jan Diekmann, Mustafa Diken, Uğur Şahin
This paper describes two mRNA vaccines for tuberculosis that are immunogenic, well-tolerated, and effective in rodent models, entering clinical trials.
Nature Immunology · Jun 12, 2026Peer-reviewedImmunology